Review article · 2009 · Open access

Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188]

J. Darbá, Agnès Minoves, E. Rojo, F. Jiménez, J Rejas

European Psychiatry, 24(S1) · Published 1 January 2009 · DOI 10.1016/s0924-9338(09)71420-8

Open PDFView at the publisherCite this paper

In brief

“Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188]” is a 2009 review article by J. Darbá and 4 co-authors, published in European Psychiatry. OpenAlex counts 1 citations as of 20 November 2026. It is open access: the full text is free to read at European Psychiatry.

Citations
1
Field-weighted impact
0.04
Authors
5

Abstract

Purpose: To examine the efficacy of second-generation-antipsychotics (SGAs) in the treatment of negative symptoms in Schizophrenia. Methods: Two meta-analyses were carried out using placebo or haloperidol as comparators. Studies were identified by searching for randomized, double-blind, placebo and/or haloperidol -controlled trials reporting data on efficacy of SGAs. Search was extended to the following databases: Pubmed, the Cochrane Central Register of Controlled Trials, Proquest Health and Medical Complete, Science Citation Index Expanded, and Current Contents Connect. the outcome measure used was the change in negative symptoms, choosing a standardized statistic (Cohen's d) to synthesize data. Results: A total of 46 homogeneous trials (Q=45.18, df=50, p=0.667, I2=0%) were included. in the placebo-controlled meta-analysis, the effect sizes (Cohen's d) obtained for amisulpride, haloperidol, olanzapine, quetiapine, risperidone and ziprasidone were 0.52, 0.34, 0.43, 0.36, 0.40 and 0.46, respectively, favoring active treatment against placebo (p< 0.001 in all cases). Comparing SGAs against haloperidol, showed just a statistically significant trend favoring SGA's in treatment of negative symptoms (Cohen's d = 0.15, p=0.008). Comparisons by drug showed a significant low and low-to-moderate standardized mean favoring SGA: Cohen's d = 0.34, p< 0.001; Cohen's d = 0.27, p< 0.001 and Cohen's d = 0.19, p=0.030, respectively for ziprasidone, risperidone and olanzapine. Conclusion: Most antipsychotics (aminosulpride, haloperidol, olanzapine. quetiapine, risperidone, ziprasidone) are effective in treatment of negative symptoms, showing moderate effect sizes. Amisulpride and ziprasidone were slightly better than the rest of drugs when compared with placebo. Compared with haloperidol, SGA showed controversial results.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Darbá, J., Minoves, A., Rojo, E., Jiménez, F., & Rejas, J. (2009). Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188]. European Psychiatry, 24(S1). https://doi.org/10.1016/s0924-9338(09)71420-8

MLA 9

Darbá, J., et al. “Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188].” European Psychiatry, vol. 24, no. S1, 2009. https://doi.org/10.1016/s0924-9338(09)71420-8.

Chicago

Darbá, J., Agnès Minoves, E. Rojo, F. Jiménez, and J Rejas. 2009. “Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188].” European Psychiatry 24 (S1). https://doi.org/10.1016/s0924-9338(09)71420-8.

Harvard

Darbá, J. et al. (2009) ‘Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188]’, European Psychiatry, 24(S1). doi:10.1016/s0924-9338(09)71420-8.

IEEE

J. Darbá, A. Minoves, E. Rojo, F. Jiménez, and J. Rejas, “Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188],” European Psychiatry, vol. 24, no. S1, 2009, doi: 10.1016/s0924-9338(09)71420-8.

BibTeX

@article{darba2009antipsychotics,
  title     = {{Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188]}},
  author    = {Darbá, J. and Minoves, Agnès and Rojo, E. and Jiménez, F. and Rejas, J},
  journal   = {European Psychiatry},
  year      = {2009},
  volume    = {24},
  number    = {S1},
  doi       = {10.1016/s0924-9338(09)71420-8},
  url       = {https://doi.org/10.1016/s0924-9338(09)71420-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • schizophrenia
  • negative symptoms
  • atypical antipsychotics
  • amisulpride
  • haloperidol
  • olanzapine
  • quetiapine
  • risperidone

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Darbá, J., Minoves, A., Rojo, E., Jiménez, F., & Rejas, J. (2009). Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials [P03-188]. European Psychiatry, 24(S1). https://doi.org/10.1016/s0924-9338(09)71420-8

How many times has this paper been cited?

1 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Psychiatry: sign in and open the PDF from this page.

Who wrote this paper?

J. Darbá, Agnès Minoves, E. Rojo, F. Jiménez, J Rejas.

What is the DOI of this paper?

10.1016/s0924-9338(09)71420-8, permanently at https://doi.org/10.1016/s0924-9338(09)71420-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.